MedTech Strategist Features RebrAIn’s Precision Targeting Solutions for Parkinson’s Disease

We are delighted to share that MedTech Strategist has featured RebrAIn in their latest issue.

The article explores how our supervised AI-driven platform, OptimMRI, simplifies precision targeting for Deep Brain Stimulation (DBS) in Parkinson’s Disease. By enhancing accuracy and reducing costs, RebrAIn aims to make DBS procedures faster, safer, and more accessible. Our innovative approach is set to transform neurosurgical practices, offering improved outcomes for patients.

Read more about our advancements and future plans in the full PDF version of the article.

Our latest public updates

Rebrain x Worldwide Dystonia Research Center

May 28, 2026

Partnership aims to develop next-generation data-driven models for personalized deep brain stimulation (DBS) targeting, expanding clinical applications from Parkinson’s disease and essential tremor to dystonia and severe pediatric dystonia with global scalability...

Rebrain unveils its identity: a strong vision for the future of assisted neurosurgery

May 21, 2026

At Rebrain, innovation has never been an end in itself. It has always been a means to improve the precision of neurosurgical procedures and to have a concrete impact on patients’ lives. Today, we are reaching a new stage of our development with the official launch of...

RebrAin 2025/2026: Expanding Reach, Driving Innovation

Jan 5, 2026

Transatlantic expansion RebrAIn’s focus for 2026 is expanding our reach to major neurosurgery reference centers in the US and Europe. Today, our top partner centers by volume are Duke University, University of Virginia (UVA), Pamplona and UCLA. These collaborations...

« Older Entries